Company: DRTSW
Filing Date: 2025-04-28
Form Type: 6-K
Source: 0001213900-25-035812
Chunk: 0

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2025

Commission File Number: 001-41316

Alpha Tau Medical Ltd.

(Exact Name of Registrant as Specified in Its Charter)

Kiryat HaMada St. 5

Jerusalem, Israel 9777605

+972 (3) 577-4115

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒ Form
40-F ☐

CONTENTS</div>

Registered Direct Offering

On April 24, 2025, Alpha Tau Medical Ltd. (the "Company")
entered into a share purchase agreement (the “Purchase Agreement”) with Oramed Ltd. (the “Investor”) for the sale
by the Company of 14,110,121 (the “Shares”) of its ordinary shares, no par value per share (the “Ordinary Shares”),
in a registered direct offering (the “Offering”), at a purchase price of $2.612 per share. The closing of the Offering occurred
on April 28, 2025 (the “Closing Date”).

The Purchase Agreement contains customary representations, warranties
and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties,
and termination provisions.

The Company received net proceeds of approximately $36.7 million from
the Offering, after deducting the estimated offering expenses payable by the Company. The Company intends to use the net proceeds from
the Offering for general corporate purposes, including research and development-related purposes in connection with its product candidates,
for expansion of its manufacturing capabilities and for potential commercialization of its product candidates.

In addition, pursuant to the terms of the Purchase Agreement, on or
before the three month anniversary of the Closing Date, the Investor shall have the right to nominate two persons to serve as directors
on the Company’s Board of Directors, subject to approval by the Company’s Nominating and Corporate governance Committee and
other customary conditions.

The Shares were offered pursuant